WFIKKN2
WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2 is a protein that in humans is encoded by the WFIKKN2 gene.[5]
Function
The WFIKKN1 protein contains a WAP domain, follistatin domain, immunoglobulin domain, two tandem Kunitz domains, and an NTR domain. This gene encodes a WFIKKN1-related protein which has the same domain organization as the WFIKKN1 protein. The WAP-type, follistatin type, Kunitz-type, and NTR-type protease inhibitory domains may control the action of multiple types of proteases. [provided by RefSeq, Jul 2008]. ##Evidence-Data-START## Transcript exon combination :: AY358142.1, AK127743.1 [ECO:0000332] RNAseq introns :: single sample supports all introns ERS025083, ERS025084 [ECO:0000348] ##Evidence-Data-END##
See also
- Kazal-type serine protease inhibitor domain
References
- GRCh38: Ensembl release 89: ENSG00000173714 - Ensembl, May 2017
- GRCm38: Ensembl release 89: ENSMUSG00000044177 - Ensembl, May 2017
- "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- "Entrez Gene: WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2".
Further reading
- Szláma G, Kondás K, Trexler M, Patthy L (December 2010). "WFIKKN1 and WFIKKN2 bind growth factors TGFβ1, BMP2 and BMP4 but do not inhibit their signalling activity". The FEBS Journal. 277 (24): 5040–50. doi:10.1111/j.1742-4658.2010.07909.x. PMID 21054789.
- Hill JJ, Qiu Y, Hewick RM, Wolfman NM (June 2003). "Regulation of myostatin in vivo by growth and differentiation factor-associated serum protein-1: a novel protein with protease inhibitor and follistatin domains". Molecular Endocrinology. 17 (6): 1144–54. doi:10.1210/me.2002-0366. PMID 12595574.
- Kondás K, Szláma G, Trexler M, Patthy L (August 2008). "Both WFIKKN1 and WFIKKN2 have high affinity for growth and differentiation factors 8 and 11". The Journal of Biological Chemistry. 283 (35): 23677–84. doi:10.1074/jbc.M803025200. PMC 3259755. PMID 18596030.
- Nagy A, Trexler M, Patthy L (May 2003). "Expression, purification and characterization of the second Kunitz-type protease inhibitor domain of the human WFIKKN protein". European Journal of Biochemistry. 270 (9): 2101–7. doi:10.1046/j.1432-1033.2003.03593.x. PMID 12709070.
- Dieli-Conwright CM, Spektor TM, Rice JC, Sattler FR, Schroeder ET (May 2012). "Hormone therapy and maximal eccentric exercise alters myostatin-related gene expression in postmenopausal women". Journal of Strength and Conditioning Research. 26 (5): 1374–82. doi:10.1519/JSC.0b013e318251083f. PMID 22395277.
- Saremi A, Gharakhanloo R, Sharghi S, Gharaati MR, Larijani B, Omidfar K (April 2010). "Effects of oral creatine and resistance training on serum myostatin and GASP-1". Molecular and Cellular Endocrinology. 317 (1–2): 25–30. doi:10.1016/j.mce.2009.12.019. PMID 20026378.
- Trexler M, Bányai L, Patthy L (January 2002). "Distinct expression pattern of two related human proteins containing multiple types of protease-inhibitory modules". Biological Chemistry. 383 (1): 223–8. doi:10.1515/BC.2002.023. PMID 11928817.
This article incorporates text from the United States National Library of Medicine, which is in the public domain.